RAS mutated
-
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Phase 3 · randomised · 430 people · 1 site in China · Recruiting now
-
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Phase 2 · randomised · 150 people · 10 sites in 2 countries · Recruiting now
-
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Phase 3 · randomised · 461 people · 419 sites in 32 countries · Running, not taking new patients
-
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Phase 3 · randomised · 450 people · 291 sites in 35 countries · Recruiting now
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer
Phase 3 · randomised · 477 people · 223 sites in 29 countries · Recruiting now